Recently, the 2024 Misi Conference (China's Pharmaceutical and Health Industry Synergy Conference), organized by the authoritative pharmaceutical information service platform Menet, opened in Huzhou. At the event, the highly anticipated "2023 Top 100 Chinese Pharmaceutical Companies" list was officially unveiled. Shanghai Huanghai Pharmaceutical Co., Ltd. (henceforth "Shanghai Huanghai Pharmaceutical"), a subsidiary of Shanghai Baheal Pharmaceutical Co., Ltd. (henceforth "Baheal Pharma"), was prominently featured on the "2023 Top 100 Traditional Chinese Medicine Companies" list, thanks to its strong capabilities in modern traditional Chinese medicine research and production.

The "Top 100 Chinese Pharmaceutical Companies" list focuses on the innovation and professional promotion capabilities of pharmaceutical industrial enterprises. Menet conducted a quantitative analysis using its exclusive data from three major terminals and six market terminals, ultimately compiling five sub-lists, including the "Top 100 Traditional Chinese Medicine (TCM) Companies." This authoritative and representative evaluation activity serves as a benchmark for enhancing the comprehensive strength and expanding the brand influence of domestic pharmaceutical industrial enterprises. It showcases the excellence of pharmaceutical brands and guides the pharmaceutical and health industries toward steady, rapid, and sustainable development.

Shanghai Huanghai Pharmaceutical, a leading ethnic TCM and natural medicine enterprise under Baheal Pharma, is dedicated to advancing TCM modernization through technological innovation. Adhering to the principles of diagnosable diseases, controllable quality, and verifiable efficacy, Shanghai Huanghai Pharmaceutical has established a modern, standardized, and internationalized TCM research and production system. This system encompasses the entire TCM industrial chain, from raw material cultivation and processing, TCM extraction to finished product formulation, and commercialization. Additionally, Shanghai Huanghai Pharmaceutical has achieved multiple management system certifications and the "Green Factory" certification by Shanghai, marking its professional capabilities in standardized, regulated, and refined management in production and operations.

The independently developed new drugs with full proprietary intellectual property rights, "Fuzheng Huayu Capsules (Tablets)" and "Qishe Pill," have both been awarded the Second Prize of the National Science and Technology Progress Award. Notably, "Fuzheng Huayu Capsules (Tablets)," an innovative TCM product for treating liver fibrosis, is the first Chinese TCM in the hepatology field to complete a Phase II clinical trial approved by the U.S. FDA. This product has pioneered a new era of dual therapy for antiviral and antifibrosis treatment of liver diseases. Over the past 20 years since its market introduction, Fuzheng Huayu has conducted 68 randomized controlled trials (RCTs) and participated in the National 12th Five-Year Major Special Project, providing robust and reliable evidence from clinical studies for reversing liver fibrosis and cirrhosis. Currently, Fuzheng Huayu maintains the top market share in the liver fibrosis treatment segment.

Beyond its advancements in modern TCM, Shanghai Huanghai Pharmaceutical's parent company, Baheal Pharma, focuses on the R&D and production of high-end sustained and controlled release formulations, including osmotic pumps, pellet coating, and matrix tablets. The sustained and controlled release formulation R&D and production base in Qingdao has repeatedly achieved "zero defects" in cGMP certifications by the U.S. FDA, enabling simultaneous production and sales in both China and the U.S. The self-developed diabetes medication Metformin Nida® (Metformin Hydrochloride Extended-Release Tablets)is the first domestically approved osmotic pump-controlled release Metformin, requiring only once-daily dosing for stable blood sugar control, significantly improving patient compliance. Nida® received U.S. approval at the end of 2018 and was launched internationally the following year. Additionally, Nida® was included in the National Reimbursement Drug List in 2023, achieving a domestic replacement of high-end formulations.

As a rising force in China's pharmaceutical industry, Baheal Pharma focuses on breakthroughs in the treatment of refractory diseases, continuously increasing R&D investment and fostering innovative collaborations. The company is currently expanding its pipeline at its modern TCM R&D and production base in Shanghai and its sustained-release formulation R&D and production base in Qingdao. With these upgrades and capacity enhancements, Baheal’s manufacturing capabilities are set to further improve. Additionally, Baheal Pharma is collaborating closely with national research institutions to advance innovative projects in high-end formulations, modern TCM, and natural drug products.

Looking ahead, Baheal Pharma is poised to harness the dual opportunities of "innovation" and "creation" within China's pharmaceutical landscape. The company plans to advance both modern traditional Chinese medicine and high-end pharmaceutical formulations, aiming to sustain its internal vitality and growth in the healthcare sector. By leveraging technological innovation, Baheal seeks to improve medical solutions and contribute significantly to global health.